Neumora Therapeutics Stock Jumps, Analyst Sees Upside In Alzheimer's Treatment

Alzheimer's Disease Agitation Data - NMRA-511 demonstrated a favorable safety profile with no somnolence or sedation and significant improvements in agitation, with placebo-adjusted CMAI total score changes of -2.6 and -2.1 at Weeks 6 and 8, respectively [2] - Patients with elevated anxiety showed improvements of -7.6 and -5.6 at the same weeks [2] - William Blair projects peak U.S. sales of NMRA-511 to reach $1.8 billion, indicating promising early data despite previous setbacks with the V1a receptor antagonist approach [2] Obesity Update - Positive Phase 2 data for NMRA-215 in obesity is anticipated by year-end 2026, which could be a significant inflection point for Neumora [3] - William Blair has incorporated value into the Neumora model for NMRA-215, estimating a 15% probability of success that could unlock a market opportunity exceeding $2 billion under conservative assumptions [3] Depression Assets - The KOASTAL-2/3 trials of monotherapy navacaprant in major depressive disorder are expected to report results in the second quarter of 2026 [4] - There is intrigue surrounding the update in the KOR antagonist space, although caution is advised regarding the de-risking value of navacaprant [4] - NMRA stock experienced a 7.50% increase, reaching $3.45 at the last check [4]